Poland· PL-100502973

Selexipag Accord

A selexipag product containing selexipagum, registered in Poland by Accord Healthcare Polska Sp. z o.o.. The same ATC class is registered in 13 of our 19 countries.

ATC B01AC27

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedSelexipag AccordATCB01AC27REGISTER NO.PL-100502973PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Selexipag is registered in 13 of 19 countries.

Countries holding a registration under ATC B01AC27 (selexipag), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose

Selexipag · ATC B01AC27

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of selexipag costs, country by country.

Normalised to the WHO defined daily dose (1.8 mg), the median price runs from $809.99 in Switzerland to $1232.99 in Italy — a ×1.5 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Selexipag · price per daily dose (1.8 mg)

USD · FX 28 Sept 2026

  • IT Italy$1232.99
  • CH Switzerland$809.99
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Selexipagum
Manufacturer
Accord Healthcare Polska Sp. z o.o.
Country
Poland (PL)
ATC code
B01AC27
ATC class
Selexipag
Defined daily dose
1.8 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05056842803649

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

237 interactions on record for selexipag.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Selexipag · interactions on record

237 records

  • 1 severe
  • 232 moderate
  • 4 minor

Most severe, free to view

  • GemfibrozilC10AB04severe
  • PapaverineA03AD01moderate
  • MannitolA06AD16moderate
  • GlycerolA06AX01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Selexipag in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All selexipag products

Authorised across Europe · EMA

The same active substance is authorised in 18 EEA countries. Names it is sold under:

  • Austria · Selexipag Ratiopharm
  • Cyprus · Selexipag Accord
  • Denmark · Selexipag Accord, Selexipag Stada
  • Estonia · Selexipag Stada
  • Spain · Selexipag Accord, Selexipag Stada
  • Greece · Xipeno
  • Croatia · Seleksipag Accord
  • Ireland · Selexipag Accord, Selexipag Clonmel
  • Iceland · Selexipag Stada, Uptravi
  • Italy · Selexipag Accord, Selexipag Eg
  • Liechtenstein · Uptravi
  • Lithuania · Selexipag Stada
  • Latvia · Selexipag Stada
  • Malta · Selexipag Clonmel
  • Netherlands · Seleksipag Accord, Selexipag Abdi
  • Norway · Selexipag Accord, Selexipag Stada
  • Portugal · Selexipag Accord, Selexipag Teva
  • Sweden · Selexipag, Selexipag Accord

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/57e84307-2f23-4e4e-a059-0bd4ece4c184
GET /v1/drugs/57e84307-2f23-4e4e-a059-0bd4ece4c184?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "1400 mcg",
  "packaging": "05056842803649 ¦ Rpz ¦ 167067\n60 tabl.",
  "substance": "Selexipagum 1.4 mg",
  "common_name": "Selexipagum",
  "pl_product_id": "100502973",
  "pozwolenie_nr": "29638",
  "auth_procedure": "DCP",
  "authorisation_validity": "2031-04-03"
}

See everything about selexipag.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.